EOLS
Evolus, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$9.30
+2.76%Margins
Gross margin
66.2%
EBITDA margin
-3.2%
EBIT margin
-7.3%
Net margin
-10.8%
FCF margin
-6.4%
111.1%
Return on equity
-13.8%
Return on assets
-17.3%
Return on invested capital
1.35x
Asset turnover
-$15.4M
Cash from operations
$0.68
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026